PARIS--French pharmaceutical company Sanofi SA (SAN.FR) and Belgium's UCB (UCB.BT) Tuesday agreed to jointly seek and develop new anti-inflammatory molecules to treat immune-mediated diseases in areas like gastroenterology and arthritis.

Sanofi and UCB will share costs and profits equally and UCB will be paid to for preclinical and clinical development that may surpass 100 million euros ($139 million).

Write to Inti Landauro at inti.landauro@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi Charts.